Ketamine is rarely lethal, but an overdose can cause unconsciousness and dangerously slowed breathing, according to the Drug ...

Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of $80 million in Series A funding. The company is developing an easy-to-use ...

Hopes for the use of oxytocin as a therapy for mood and attachment disorders have been confounded by the wide-ranging effects ...

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Mosanna Therapeutics ("the Company"). The clinical-stage biotech company headquartered in Basel, Switzerland, is developing ...

While its effectiveness is still being researched, clinical therapists across the country and here at Bryan Medical say it’s mostly beneficial for treatment-resistant depression patients.

The universe of mental health clinics offering ketamine, an anesthetic with mind-bending effects, is expanding as New Yorkers ...

T he U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression.Johnson & Johnson said patients ...

Opioid overdoses are a major public health issue in the U.S., killing tens of thousands of people every year. The medicine ...

Postnatal depression occurs in approximately 20% ... All mothers were invited to use a nasal spray prior to breastfeeding which contained either the oxytocin hormone or a placebo.

A 34-year-old man was admitted to the hospital because of left ear pain with hearing loss and facial droop on the left side.

The field is expanding quickly, and often without clear rules. Though the FDA has approved one ketamine-based nasal spray for depression, most clinics offer intravenous infusions of ketamine, an ...